Flow promoting ocular implant device and methods
View Patent ↗Disclosed are devices and methods for treatment of eye disease such as glaucoma. Implants are described herein that create a flow field, such as between the anterior chamber and either the supraciliary space or suprachoroidal space. In addition, the implant can be treated with one or more treatments, including plasma treatments, for creating a variety of surface features and characteristics. Some of the surface features and characteristics can assist in controlling tissue responses to the implanted implant, including promoting or preventing tissue proliferation.
1. A method of treating an ocular implant for creating surface features comprising:
treating the ocular implant with a plasma treatment configured to alter a tissue response of the implant wherein the ocular implant includes an elongate tubular body comprising a proximal end, a distal end and a straight, inner lumen extending at least partway between the proximal end and the distal end, the implant having a fenestration extending from an outer surface of the tubular body and intersecting with the inner lumen, and wherein the implant includes an extruded feature extending from the outer surface of the tubular body adjacent the proximal end, and wherein treating the ocular implant includes treating a first length of the ocular implant with a first type of surface treatment and treating a second length of the ocular implant adjacent the distal end with a second type of surface treatment, and wherein the first type of surface treatment promotes tissue proliferation and the second type of surface treatment prevents tissue proliferation.
2. The method of claim 1 , wherein the plasma treatment process creates a micro-layer of material on the surface of the implant which has a different surface chemistry from the substrate material of the implant.
3. The ocular implant of claim 2 , wherein the micro-layer of material is a polyolefin resin.
4. The ocular implant of claim 2 , wherein the micro-layer of material is a fluoropolymer.
5. The ocular implant of claim 2 , wherein the micro-layer of material is a polyethylene glycol derivative.
6. The method of claim 2 , wherein the plasma treatment is a plasma enhanced chemical vapor deposition process.
7. The method of claim 2 , wherein the lumen is non-coiled.
8. The method of claim 1 , further comprising implanting the ocular implant in an eye such that the distal end is in a suprachoroidal space or supraciliary space and the proximal end is in an anterior chamber of the eye.